http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 03 Apr 2026 16:41:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++FWP++++++++INNOCAN+PHARMA+Corp++++++++++++++++++++Filed+by%3A+INNOCAN+PHARMA+Corp/26272290.html si-local-file:///var/storage/secattach/20260403/26272290.html http://www.streetinsider.com/SEC+Filings/Form++FWP++++++++INNOCAN+PHARMA+Corp++++++++++++++++++++Filed+by%3A+INNOCAN+PHARMA+Corp/26272290.html Fri, 03 Apr 2026 16:41:00 -0400 INNO INNPD O.46550843 http://www.streetinsider.com/SEC+Filings/Form++FWP++++++++INNOCAN+PHARMA+Corp++++++++++++++++++++Filed+by%3A+INNOCAN+PHARMA+Corp/26272290.html si-local-file:///var/storage/secattach/20260403/26272290.html http://www.streetinsider.com/SEC+Filings/Form++FWP++++++++INNOCAN+PHARMA+Corp++++++++++++++++++++Filed+by%3A+INNOCAN+PHARMA+Corp/26272290.html Fri, 03 Apr 2026 16:41:00 -0400 INNO INNPD O.46550843 http://www.streetinsider.com/SEC+Filings/Form++FWP++++++++INNOCAN+PHARMA+Corp++++++++++++++++++++Filed+by%3A+INNOCAN+PHARMA+Corp/26272290.html si-local-file:///var/storage/secattach/20260403/26272290.html http://www.streetinsider.com/SEC+Filings/Form++FWP++++++++INNOCAN+PHARMA+Corp++++++++++++++++++++Filed+by%3A+INNOCAN+PHARMA+Corp/26272290.html Fri, 03 Apr 2026 16:41:00 -0400 INNO INNPD O.46550843 http://www.streetinsider.com/SEC+Filings/Form++F-1A++++++INNOCAN+PHARMA+Corp++++++++++++++++++/26272188.html si-local-file:///var/storage/secattach/20260403/26272188.html http://www.streetinsider.com/SEC+Filings/Form++F-1A++++++INNOCAN+PHARMA+Corp++++++++++++++++++/26272188.html Fri, 03 Apr 2026 16:31:00 -0400 INNO INNPD O.46550843 http://www.streetinsider.com/SEC+Filings/Form++F-1A++++++INNOCAN+PHARMA+Corp++++++++++++++++++/26272188.html si-local-file:///var/storage/secattach/20260403/26272188.html http://www.streetinsider.com/SEC+Filings/Form++F-1A++++++INNOCAN+PHARMA+Corp++++++++++++++++++/26272188.html Fri, 03 Apr 2026 16:31:00 -0400 INNO INNPD O.46550843 http://www.streetinsider.com/SEC+Filings/Form++F-1A++++++INNOCAN+PHARMA+Corp++++++++++++++++++/26272188.html si-local-file:///var/storage/secattach/20260403/26272188.html http://www.streetinsider.com/SEC+Filings/Form++F-1A++++++INNOCAN+PHARMA+Corp++++++++++++++++++/26272188.html Fri, 03 Apr 2026 16:31:00 -0400 INNO INNPD O.46550843 http://www.streetinsider.com/Press+Releases/Innocan+Pharma+Reports+2025+Financial+Results%2C+with+Revenues+at+US+%2426.6M/26243339.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/il..herzliy" idsrc="xmltag.org" >HERZLIYA, Israel</location> and <location value="LU/ca.ab.calgry" idsrc="xmltag.org" >CALGARY, AB</location></span>, <span class="legendSpanClass"><chron>March 31, 2026</chron></span> /PRNewswire/ -- <span value="CNSX:INNO" idsrc="xmltag.org" >Innocan Pharma Corporation</span> (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the "<b>Company</b>" or "<b>Innocan</b>"), a pharmaceutical technology company focusing on developing innovative drug delivery platform technologies, is pleased to announce its audited financial consolidated results for the year ended <chron>December 31, 2025</chron>.</p> <div id="prni_dvprnejpga5bcleft" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpga5bcleft" title="Innocan Pharma Logo" src="https://mma.prnewswire.com/media/2570689/Innocan_Pharma_Logo.jpg" alt="Innocan Pharma Logo" align="middle" /></div><p>Iris Bincovich, CEO of Innocan commented, "We remain firmly focused on executing our strategy and advancing our long-term objectives in the healthcare sector.</p><p>Our http://www.streetinsider.com/Press+Releases/Innocan+Pharma+Reports+2025+Financial+Results%2C+with+Revenues+at+US+%2426.6M/26243339.html Tue, 31 Mar 2026 03:00:00 -0400 INNO INNPF IP4 O.46550843 http://www.streetinsider.com/Press+Releases/Innocan+Pharma+Reports+2025+Financial+Results%2C+with+Revenues+at+US+%2426.6M/26243339.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/il..herzliy" idsrc="xmltag.org" >HERZLIYA, Israel</location> and <location value="LU/ca.ab.calgry" idsrc="xmltag.org" >CALGARY, AB</location></span>, <span class="legendSpanClass"><chron>March 31, 2026</chron></span> /PRNewswire/ -- <span value="CNSX:INNO" idsrc="xmltag.org" >Innocan Pharma Corporation</span> (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the "<b>Company</b>" or "<b>Innocan</b>"), a pharmaceutical technology company focusing on developing innovative drug delivery platform technologies, is pleased to announce its audited financial consolidated results for the year ended <chron>December 31, 2025</chron>.</p> <div id="prni_dvprnejpga5bcleft" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpga5bcleft" title="Innocan Pharma Logo" src="https://mma.prnewswire.com/media/2570689/Innocan_Pharma_Logo.jpg" alt="Innocan Pharma Logo" align="middle" /></div><p>Iris Bincovich, CEO of Innocan commented, "We remain firmly focused on executing our strategy and advancing our long-term objectives in the healthcare sector.</p><p>Our http://www.streetinsider.com/Press+Releases/Innocan+Pharma+Reports+2025+Financial+Results%2C+with+Revenues+at+US+%2426.6M/26243339.html Tue, 31 Mar 2026 03:00:00 -0400 INNO INNPF IP4 O.46550843 http://www.streetinsider.com/Press+Releases/Innocan+Pharma+Reports+2025+Financial+Results%2C+with+Revenues+at+US+%2426.6M/26243339.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/il..herzliy" idsrc="xmltag.org" >HERZLIYA, Israel</location> and <location value="LU/ca.ab.calgry" idsrc="xmltag.org" >CALGARY, AB</location></span>, <span class="legendSpanClass"><chron>March 31, 2026</chron></span> /PRNewswire/ -- <span value="CNSX:INNO" idsrc="xmltag.org" >Innocan Pharma Corporation</span> (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the "<b>Company</b>" or "<b>Innocan</b>"), a pharmaceutical technology company focusing on developing innovative drug delivery platform technologies, is pleased to announce its audited financial consolidated results for the year ended <chron>December 31, 2025</chron>.</p> <div id="prni_dvprnejpga5bcleft" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpga5bcleft" title="Innocan Pharma Logo" src="https://mma.prnewswire.com/media/2570689/Innocan_Pharma_Logo.jpg" alt="Innocan Pharma Logo" align="middle" /></div><p>Iris Bincovich, CEO of Innocan commented, "We remain firmly focused on executing our strategy and advancing our long-term objectives in the healthcare sector.</p><p>Our http://www.streetinsider.com/Press+Releases/Innocan+Pharma+Reports+2025+Financial+Results%2C+with+Revenues+at+US+%2426.6M/26243339.html Tue, 31 Mar 2026 03:00:00 -0400 INNO INNPF IP4 O.46550843 http://www.streetinsider.com/Press+Releases/Innocan+Pharma+Reports+2025+Financial+Results%2C+with+Revenues+at+US+%2426.6M/26243339.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/il..herzliy" idsrc="xmltag.org" >HERZLIYA, Israel</location> and <location value="LU/ca.ab.calgry" idsrc="xmltag.org" >CALGARY, AB</location></span>, <span class="legendSpanClass"><chron>March 31, 2026</chron></span> /PRNewswire/ -- <span value="CNSX:INNO" idsrc="xmltag.org" >Innocan Pharma Corporation</span> (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the "<b>Company</b>" or "<b>Innocan</b>"), a pharmaceutical technology company focusing on developing innovative drug delivery platform technologies, is pleased to announce its audited financial consolidated results for the year ended <chron>December 31, 2025</chron>.</p> <div id="prni_dvprnejpga5bcleft" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpga5bcleft" title="Innocan Pharma Logo" src="https://mma.prnewswire.com/media/2570689/Innocan_Pharma_Logo.jpg" alt="Innocan Pharma Logo" align="middle" /></div><p>Iris Bincovich, CEO of Innocan commented, "We remain firmly focused on executing our strategy and advancing our long-term objectives in the healthcare sector.</p><p>Our http://www.streetinsider.com/Press+Releases/Innocan+Pharma+Reports+2025+Financial+Results%2C+with+Revenues+at+US+%2426.6M/26243339.html Tue, 31 Mar 2026 03:00:00 -0400 INNO INNPF IP4 O.46550843 http://www.streetinsider.com/PRNewswire/Innocan+Pharma+Reports+2025+Financial+Results%2C+with+Revenues+at+US+%2426.6M/26243339.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/il..herzliy" idsrc="xmltag.org" >HERZLIYA, Israel</location> and <location value="LU/ca.ab.calgry" idsrc="xmltag.org" >CALGARY, AB</location></span>, <span class="legendSpanClass"><chron>March 31, 2026</chron></span> /PRNewswire/ -- <span value="CNSX:INNO" idsrc="xmltag.org" >Innocan Pharma Corporation</span> (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the "<b>Company</b>" or "<b>Innocan</b>"), a pharmaceutical technology company focusing on developing innovative drug delivery platform technologies, is pleased to announce its audited financial consolidated results for the year ended <chron>December 31, 2025</chron>.</p> <div id="prni_dvprnejpga5bcleft" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpga5bcleft" title="Innocan Pharma Logo" src="https://mma.prnewswire.com/media/2570689/Innocan_Pharma_Logo.jpg" alt="Innocan Pharma Logo" align="middle" /></div><p>Iris Bincovich, CEO of Innocan commented, "We remain firmly focused on executing our strategy and advancing our long-term objectives in the healthcare sector.</p><p>Our http://www.streetinsider.com/PRNewswire/Innocan+Pharma+Reports+2025+Financial+Results%2C+with+Revenues+at+US+%2426.6M/26243339.html Tue, 31 Mar 2026 03:00:00 -0400 INNO INNPF IP4 O.46550843 http://www.streetinsider.com/PRNewswire/Innocan+Pharma+Reports+2025+Financial+Results%2C+with+Revenues+at+US+%2426.6M/26243339.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/il..herzliy" idsrc="xmltag.org" >HERZLIYA, Israel</location> and <location value="LU/ca.ab.calgry" idsrc="xmltag.org" >CALGARY, AB</location></span>, <span class="legendSpanClass"><chron>March 31, 2026</chron></span> /PRNewswire/ -- <span value="CNSX:INNO" idsrc="xmltag.org" >Innocan Pharma Corporation</span> (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the "<b>Company</b>" or "<b>Innocan</b>"), a pharmaceutical technology company focusing on developing innovative drug delivery platform technologies, is pleased to announce its audited financial consolidated results for the year ended <chron>December 31, 2025</chron>.</p> <div id="prni_dvprnejpga5bcleft" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpga5bcleft" title="Innocan Pharma Logo" src="https://mma.prnewswire.com/media/2570689/Innocan_Pharma_Logo.jpg" alt="Innocan Pharma Logo" align="middle" /></div><p>Iris Bincovich, CEO of Innocan commented, "We remain firmly focused on executing our strategy and advancing our long-term objectives in the healthcare sector.</p><p>Our http://www.streetinsider.com/PRNewswire/Innocan+Pharma+Reports+2025+Financial+Results%2C+with+Revenues+at+US+%2426.6M/26243339.html Tue, 31 Mar 2026 03:00:00 -0400 INNO INNPF IP4 O.46550843 http://www.streetinsider.com/PRNewswire/Innocan+Pharma+Reports+2025+Financial+Results%2C+with+Revenues+at+US+%2426.6M/26243339.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/il..herzliy" idsrc="xmltag.org" >HERZLIYA, Israel</location> and <location value="LU/ca.ab.calgry" idsrc="xmltag.org" >CALGARY, AB</location></span>, <span class="legendSpanClass"><chron>March 31, 2026</chron></span> /PRNewswire/ -- <span value="CNSX:INNO" idsrc="xmltag.org" >Innocan Pharma Corporation</span> (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the "<b>Company</b>" or "<b>Innocan</b>"), a pharmaceutical technology company focusing on developing innovative drug delivery platform technologies, is pleased to announce its audited financial consolidated results for the year ended <chron>December 31, 2025</chron>.</p> <div id="prni_dvprnejpga5bcleft" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpga5bcleft" title="Innocan Pharma Logo" src="https://mma.prnewswire.com/media/2570689/Innocan_Pharma_Logo.jpg" alt="Innocan Pharma Logo" align="middle" /></div><p>Iris Bincovich, CEO of Innocan commented, "We remain firmly focused on executing our strategy and advancing our long-term objectives in the healthcare sector.</p><p>Our http://www.streetinsider.com/PRNewswire/Innocan+Pharma+Reports+2025+Financial+Results%2C+with+Revenues+at+US+%2426.6M/26243339.html Tue, 31 Mar 2026 03:00:00 -0400 INNO INNPF IP4 O.46550843 http://www.streetinsider.com/PRNewswire/Innocan+Pharma+Reports+2025+Financial+Results%2C+with+Revenues+at+US+%2426.6M/26243339.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/il..herzliy" idsrc="xmltag.org" >HERZLIYA, Israel</location> and <location value="LU/ca.ab.calgry" idsrc="xmltag.org" >CALGARY, AB</location></span>, <span class="legendSpanClass"><chron>March 31, 2026</chron></span> /PRNewswire/ -- <span value="CNSX:INNO" idsrc="xmltag.org" >Innocan Pharma Corporation</span> (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the "<b>Company</b>" or "<b>Innocan</b>"), a pharmaceutical technology company focusing on developing innovative drug delivery platform technologies, is pleased to announce its audited financial consolidated results for the year ended <chron>December 31, 2025</chron>.</p> <div id="prni_dvprnejpga5bcleft" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpga5bcleft" title="Innocan Pharma Logo" src="https://mma.prnewswire.com/media/2570689/Innocan_Pharma_Logo.jpg" alt="Innocan Pharma Logo" align="middle" /></div><p>Iris Bincovich, CEO of Innocan commented, "We remain firmly focused on executing our strategy and advancing our long-term objectives in the healthcare sector.</p><p>Our http://www.streetinsider.com/PRNewswire/Innocan+Pharma+Reports+2025+Financial+Results%2C+with+Revenues+at+US+%2426.6M/26243339.html Tue, 31 Mar 2026 03:00:00 -0400 INNO INNPF IP4 O.46550843 http://www.streetinsider.com/SEC+Filings/Form++FWP++++++++INNOCAN+PHARMA+Corp++++++++++++++++++++Filed+by%3A+INNOCAN+PHARMA+Corp/26167700.html si-local-file:///var/storage/secattach/20260316/26167700.html http://www.streetinsider.com/SEC+Filings/Form++FWP++++++++INNOCAN+PHARMA+Corp++++++++++++++++++++Filed+by%3A+INNOCAN+PHARMA+Corp/26167700.html Mon, 16 Mar 2026 16:46:00 -0400 INNO INNPD O.46550843 http://www.streetinsider.com/SEC+Filings/Form++FWP++++++++INNOCAN+PHARMA+Corp++++++++++++++++++++Filed+by%3A+INNOCAN+PHARMA+Corp/26167700.html si-local-file:///var/storage/secattach/20260316/26167700.html http://www.streetinsider.com/SEC+Filings/Form++FWP++++++++INNOCAN+PHARMA+Corp++++++++++++++++++++Filed+by%3A+INNOCAN+PHARMA+Corp/26167700.html Mon, 16 Mar 2026 16:46:00 -0400 INNO INNPD O.46550843 http://www.streetinsider.com/SEC+Filings/Form++FWP++++++++INNOCAN+PHARMA+Corp++++++++++++++++++++Filed+by%3A+INNOCAN+PHARMA+Corp/26167700.html si-local-file:///var/storage/secattach/20260316/26167700.html http://www.streetinsider.com/SEC+Filings/Form++FWP++++++++INNOCAN+PHARMA+Corp++++++++++++++++++++Filed+by%3A+INNOCAN+PHARMA+Corp/26167700.html Mon, 16 Mar 2026 16:46:00 -0400 INNO INNPD O.46550843 http://www.streetinsider.com/SEC+Filings/Form++F-1++++++++INNOCAN+PHARMA+Corp++++++++++++++++++/26166408.html si-local-file:///var/storage/secattach/20260316/26166408.html http://www.streetinsider.com/SEC+Filings/Form++F-1++++++++INNOCAN+PHARMA+Corp++++++++++++++++++/26166408.html Mon, 16 Mar 2026 16:02:00 -0400 INNO INNPD O.46550843 http://www.streetinsider.com/SEC+Filings/Form++F-1++++++++INNOCAN+PHARMA+Corp++++++++++++++++++/26166408.html si-local-file:///var/storage/secattach/20260316/26166408.html http://www.streetinsider.com/SEC+Filings/Form++F-1++++++++INNOCAN+PHARMA+Corp++++++++++++++++++/26166408.html Mon, 16 Mar 2026 16:02:00 -0400 INNO INNPD O.46550843 http://www.streetinsider.com/SEC+Filings/Form++F-1++++++++INNOCAN+PHARMA+Corp++++++++++++++++++/26166408.html si-local-file:///var/storage/secattach/20260316/26166408.html http://www.streetinsider.com/SEC+Filings/Form++F-1++++++++INNOCAN+PHARMA+Corp++++++++++++++++++/26166408.html Mon, 16 Mar 2026 16:02:00 -0400 INNO INNPD O.46550843 http://www.streetinsider.com/FDA/Innocan+Pharma+receives+third+consecutive+FDA+fee+waiver+for+dog+pain+drug/26082381.html <p>Innocan Pharma Corporation (CSE: INNO) (FSE: IP40) (OTCQB: INNPD) announced that the FDA's Center for Veterinary Medicine granted the company a sponsor fee waiver for its LPT-CBD product for 2026, marking the third consecutive year it has received this waiver.</p> <p>The FDA's Center for Veterinary Medicine assesses annual fees for animal drug applications. Sponsors developing products may request a fee waiver each year under the "significant barrier to innovation" provision. Innocan submits an annual renewal request that includes development progress updates and forward plans.</p> <p>The waiver applies to Innocan's Liposomal Technology-CBD drug product candidate, being developed as a subcutaneous injection for managing http://www.streetinsider.com/FDA/Innocan+Pharma+receives+third+consecutive+FDA+fee+waiver+for+dog+pain+drug/26082381.html Fri, 27 Feb 2026 16:30:33 -0400 INNO INNPD IP40 O.46550843 http://www.streetinsider.com/FDA/Innocan+Pharma+receives+third+consecutive+FDA+fee+waiver+for+dog+pain+drug/26082381.html <p>Innocan Pharma Corporation (CSE: INNO) (FSE: IP40) (OTCQB: INNPD) announced that the FDA's Center for Veterinary Medicine granted the company a sponsor fee waiver for its LPT-CBD product for 2026, marking the third consecutive year it has received this waiver.</p> <p>The FDA's Center for Veterinary Medicine assesses annual fees for animal drug applications. Sponsors developing products may request a fee waiver each year under the "significant barrier to innovation" provision. Innocan submits an annual renewal request that includes development progress updates and forward plans.</p> <p>The waiver applies to Innocan's Liposomal Technology-CBD drug product candidate, being developed as a subcutaneous injection for managing http://www.streetinsider.com/FDA/Innocan+Pharma+receives+third+consecutive+FDA+fee+waiver+for+dog+pain+drug/26082381.html Fri, 27 Feb 2026 16:30:33 -0400 INNO INNPD IP40 O.46550843 http://www.streetinsider.com/FDA/Innocan+Pharma+receives+third+consecutive+FDA+fee+waiver+for+dog+pain+drug/26082381.html <p>Innocan Pharma Corporation (CSE: INNO) (FSE: IP40) (OTCQB: INNPD) announced that the FDA's Center for Veterinary Medicine granted the company a sponsor fee waiver for its LPT-CBD product for 2026, marking the third consecutive year it has received this waiver.</p> <p>The FDA's Center for Veterinary Medicine assesses annual fees for animal drug applications. Sponsors developing products may request a fee waiver each year under the "significant barrier to innovation" provision. Innocan submits an annual renewal request that includes development progress updates and forward plans.</p> <p>The waiver applies to Innocan's Liposomal Technology-CBD drug product candidate, being developed as a subcutaneous injection for managing http://www.streetinsider.com/FDA/Innocan+Pharma+receives+third+consecutive+FDA+fee+waiver+for+dog+pain+drug/26082381.html Fri, 27 Feb 2026 16:30:33 -0400 INNO INNPD IP40 O.46550843 http://www.streetinsider.com/FDA/Innocan+Pharma+receives+third+consecutive+FDA+fee+waiver+for+dog+pain+drug/26082381.html <p>Innocan Pharma Corporation (CSE: INNO) (FSE: IP40) (OTCQB: INNPD) announced that the FDA's Center for Veterinary Medicine granted the company a sponsor fee waiver for its LPT-CBD product for 2026, marking the third consecutive year it has received this waiver.</p> <p>The FDA's Center for Veterinary Medicine assesses annual fees for animal drug applications. Sponsors developing products may request a fee waiver each year under the "significant barrier to innovation" provision. Innocan submits an annual renewal request that includes development progress updates and forward plans.</p> <p>The waiver applies to Innocan's Liposomal Technology-CBD drug product candidate, being developed as a subcutaneous injection for managing http://www.streetinsider.com/FDA/Innocan+Pharma+receives+third+consecutive+FDA+fee+waiver+for+dog+pain+drug/26082381.html Fri, 27 Feb 2026 16:30:33 -0400 INNO INNPD IP40 O.46550843 http://www.streetinsider.com/Press+Releases/FDA+Center+for+Veterinary+Medicine+Grants+Innocan+a+Fee+Waiver+in+2026+for+the+Third+Consecutive+Time/26082370.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/il..herzliy" idsrc="xmltag.org" >HERZLIYA, Israel</location> and <location value="LU/ca.ab.calgry" idsrc="xmltag.org" >CALGARY, AB</location></span>, <span class="legendSpanClass"><chron>Feb. 27, 2026</chron></span> /PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP40) (OTCQB: INNPD) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, is pleased to announce that the <span>FDA's</span> <span>Center for Veterinary Medicine</span> (CVM) has granted the Company a sponsor fee waiver for its LPT-CBD (Liposome Platform Technology-Cannabidiol) product for the third consecutive year.</p> <div id="prni_dvprnejpga661left" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpga661left" title="Innocan Pharma Corporation Logo" src="https://mma.prnewswire.com/media/2570689/Innocan_Pharma_Logo.jpg" alt="Innocan Pharma Corporation Logo" align="middle" /></div><p><span>The FDA's Center for Veterinary Medicine</span> (CVM) assesses annual fees for animal http://www.streetinsider.com/Press+Releases/FDA+Center+for+Veterinary+Medicine+Grants+Innocan+a+Fee+Waiver+in+2026+for+the+Third+Consecutive+Time/26082370.html Fri, 27 Feb 2026 16:30:00 -0400 INNO INNPD IP40 O.46550843